COMPOSITIONS AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER
Disclosed herein is a method for treating obsessive-compulsive disorder in a patient in need thereof by administering to the patient a dosage form including an effective amount of troriluzole.
1 . A method for treating obsessive-compulsive disorder in a patient in need thereof, comprising administering to the patient a dosage form comprising an effective amount of troriluzole.
2 . The method of claim 1 , wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least −3.4 points from baseline.
3 . The method of claim 1 , wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least 0.5 points compared to placebo.
4 . The method of claim 1 , wherein the dosage form is administered daily for eight weeks or longer, and wherein at week 8 the patient has a mean Y-BOCS total scale change of at least −5.1 points from baseline.
5 . The method of claim 1 , wherein the dosage form is administered daily for eight weeks or longer, and wherein the patient at week 8 has a mean Y-BOCS total scale change of at least 1.5 points compared to placebo.
6 . The method of claim 1 , wherein the dosage form is administered daily for twelve weeks or longer, and wherein at week 12 the patient has a mean Y-BOCS total scale change of −5.9 points from baseline.
7 . The method of claim 1 , wherein the dosage form is administered daily for twelve weeks or longer, and wherein the patient at week 12 has a mean Y-BOCS total scale change of 1.0 points compared to placebo.
8 . The method of claim 1 , wherein the patient has a median Y-BOCS score of 26 or greater.
9 . The method of claim 8 , wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least −4.1 points from baseline.
10 . The method of claim 8 , wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least 0.6 points compared to placebo.
11 . The method of claim 8 , wherein the dosage form is administered daily for eight weeks or longer, and wherein at week 8 the patient has a mean Y-BOCS total scale change of at least −6.0 points from baseline.
12 . The method of claim 8 , wherein the dosage form is administered daily for eight weeks or longer, and wherein the patient at week 8 has a mean Y-BOCS total scale change of at least 2.9 points compared to placebo.
13 . The method of claim 8 , wherein the dosage form is administered daily for twelve weeks or longer, and wherein at week 12 the patient has a mean Y-BOCS total scale change of −7.0 points from baseline.
14 . The method of claim 8 , wherein the dosage form is administered daily for twelve weeks or longer, and wherein the patient at week 12 has a mean Y-BOCS total scale change of 2.4 points compared to placebo.
15 . A dosage form comprising troriluzole in an amount effective to treat obsessive-compulsive disorder in a patient in need thereof.
16 . The dosage form of claim 15 , comprising troriluzole in an amount of 200 mg or greater.
17 . The dosage form of claim 15 , comprising troriluzole in an amount of 250 mg or greater.
18 . The dosage form of claim 15 , comprising troriluzole in an amount of 300 mg or greater.
19 . The dosage form of claim 15 , comprising troriluzole in an amount of 350 mg or greater.
20 . The dosage form of claim 15 , comprising troriluzole in an amount of 400 mg or greater.
21 . (canceled)
22 . (canceled)